Bullous disorders associated with anti–PD‐1 and anti–PD‐L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
暂无分享,去创建一个
J. Berk-Krauss | M. Sznol | M. Tomayko | R. Decker | D. Petrylak | W. Damsky | J. Siegel | E. Glusac | F. Castiglione | S. Goldberg | J. Leventhal | Angeliki M. Stamatouli | N. Fischbach | M. Totonchy | Navid Hafez
[1] L. Geskin,et al. A review of bullous pemphigoid associated with PD‐1 and PD‐L1 inhibitors , 2018, International journal of dermatology.
[2] B. Kwong,et al. Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy , 2017, JAAD case reports.
[3] S. Granter,et al. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid. , 2017, JAMA dermatology.
[4] J. Wargo,et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy , 2017, Journal of cutaneous pathology.
[5] M. Tomayko,et al. Development of bullous pemphigoid during nivolumab therapy , 2016, JAAD case reports.
[6] S. Gettinger,et al. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. , 2016, JAMA dermatology.
[7] R. Hui,et al. PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. , 2016, Melanoma research.
[8] J. Mazières,et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies , 2016, Current opinion in oncology.
[9] K. Byth,et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. , 2016, Journal of the American Academy of Dermatology.
[10] J. Wolchok,et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1 , 2016, Cancer Immunology Research.
[11] J. Chen,et al. CD47: a potential immunotherapy target for eliminating cancer cells , 2016, Clinical and Translational Oncology.
[12] G. Gibney,et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.
[13] T. Krenács,et al. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis , 2012, Histochemistry and Cell Biology.
[14] B. Molnár,et al. Immunophenotypic Profiling of Nonsmall Cell Lung Cancer Progression Using the Tissue Microarray Approach , 2007, Applied immunohistochemistry & molecular morphology : AIMM.